alexa
Reach Us +1-217-403-9671
Oral Drug Suspensions: Is In Vitro Dissolution Testing Relevant In Predicting The In Vivo Performance? | 33395
ISSN: 2167-7689

Pharmaceutical Regulatory Affairs: Open Access
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Oral drug suspensions: Is in vitro dissolution testing relevant in predicting the in vivo performance?

5th International Conference and Exhibition on Pharmaceutical Regulatory Affairs

Thaís dos Santos Paulino Soares, Jacqueline de Souza, Lorena de Sousa Rosa, Neila Márcia Silva Barcellos and Flávia Dias Marques Marinho

Federal University of Ouro Preto, Brazil

Posters-Accepted Abstracts: Pharmaceut Reg Affairs

DOI: 10.4172/2167-7689.S1.019

Abstract
Dissolution testing conducted in physiological similar conditions is an useful tool in predicting issues related to pharmacokinetics, may indicate bioequivalence between certain products as solid oral dosage forms, and is employed to optimize the development and ensure the quality of drug formulations. According to Brazilian Health Surveillance Agency (Anvisa), European Medicines Agency (EMA) and Food and Drug Administration (FDA), comparative dissolution testing is required as a previous stage to the bioequivalence study between the new drug application (NDA) and abbreviated new drug application (ANDA), and also between NDA and similar (ANDA designated by a trademark) in Brazil. For oral suspensions, little information is available in the literature about the dissolution testing conditions, such as insertion and collection of the sample, influence of the system agitation, and others. In 1995, the first monograph including suspension dissolution testing was published in the United States Pharmacopeia (USP) 23. Dissolution testing was mentioned in one suspension monograph in Brazilian Pharmacopoeia 4th edition (2005) which was excluded in the 5th edition (2010). In USP 36 (2013), 12 suspension monographs include the test. Currently, 13 NDA, 17 ANDA and 9 similar oral suspensions are registered in Anvisa. Out of these, two (15.4%) NDA, three (17.6%) ANDA and one (11%) similar have monographs with dissolution test in USP 36. In this scenario, the establishment of the dissolution test conditions and its relevance in predicting in vivo performance of suspensions is paramount to subsidize their registration by the regulatory agencies.
Biography

Thaís dos Santos Paulino Soares did her Master’s degree in Pharmaceutical Sciences from the Federal University of Ouro Preto. She graduated in Pharmacy, also from UFOP, in 2013. Currently, she is pursuing MBA in Regulatory Affairs at the Instituto de Pós Graduação (IPOG), in Belo Horizonte, Brazil.

Email: [email protected]

Top